Sentynl acquires Eiger’s Zokinvy to treat rare genetic disease progeria
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 May 24
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 May 24
The results showed that BI 764524 was well received upon intravitreal administration of both single and multiple doses…
03 May 24
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 May 24
As per the pre-agreed terms of the JV, Bayer has secured full ownership of the entity which was…
03 May 24
The partnership will combine Poseida Therapeutics’ allogeneic CAR-T platform with Xyphos Biosciences’ ACCEL technology to develop convertibleCAR programmes…
03 May 24
BridgeBio Oncology Therapeutics will advance the development of its oncology portfolio of three initial cancer treatment programmes, which…
03 May 24
Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870…
03 May 24
The latest Goli Gummy is made with matcha powder and Cognizin to help support focus and attention
03 May 24
Alkermes and Novo Nordisk also entered into subcontracting arrangements to continue certain development and manufacturing activities currently performed…
03 May 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services…